Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Evaluating ROR1 As a Target in Childhood Leukemia

Paraskevi Diamanti, PhD, Bethan Kathleen Bailey, BSc, Obinna Ebere Iheanacho, MD, Amit C. Nathwani, MD PhD, Allison Blair, PhD

Blood (2019) 134 (Supplement_1): 2635.

https://doi.org/10.1182/blood-2019-126734

Published: 2019

Journal Articles

PET-CT Invisible Diffuse Large B-Cell Lymphoma Features a Silent B-Cell Receptor Signaling

Dong Sheng, MD, Ting Li, MD, Xiangnan Jiang, MD, Weige Wang, MD, Y. Lynn Wang, MD PhD, Xiaoqiu Li

Blood (2017) 130 (Supplement 1): 2853.

https://doi.org/10.1182/blood.V130.Suppl_1.2853.2853

Published: 2017

Journal Articles

Histone Deacetylation Inhibitor Sensitizes T-ALLs to Topoisomerase II Inhibitor By Attenuating G2 Cell Cycle Arrest and Blocking Nuclear Entry of Ctip during DNA Repair

Jin-Hwang Liu, MD PhD, Yu-Hern Lin, MS, Hon-Wen Liu, PhD, Jyh-Pyng Gau, MD

Blood (2015) 126 (23): 4862.

https://doi.org/10.1182/blood.V126.23.4862.4862

Published: 2015

Journal Articles

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Zheng Yan, Wenqi Jiang, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 3936.

https://doi.org/10.1182/blood.V126.23.3936.3936

Published: 2015

Journal Articles

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Todd A. Fehniger, MD PhD, Robert K Stuart, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Julie Curtsinger, PhD, Timothy Mark Hillman, MSc, Nova Silver, RN, Michael Szarek, PhD, Mark W Lowdell, BSc, MSc, PhD FRCPath, Leonid Gorelik, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 2320.

https://doi.org/10.1182/blood.V124.21.2320.2320

Published: 2014

Journal Articles

A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency

Samantha Miner, Nancy F. Hensel, Bahey Salem, Neil Dunavin, MD, Kazushi Tanimoto, MD, Minoo Battiwalla, MD MS, Kit Lu, MD, Keyvan Keyvanfar, BS, Marianna Sabatino, David Stroncek, Patrick J Hanley, PhD, Catherine M. Bollard, MBChB, MD, Katayoun Rezvani, MD, PhD, Marcin Kortylewski, PhD, Pawel Muranski, MD, John Barrett, MD, Sawa Ito, MD

Blood (2014) 124 (21): 316.

https://doi.org/10.1182/blood.V124.21.316.316

Published: 2014

Journal Articles

Prognostic Implications Of Abnormal Bone Marrow Lesions In The Appendicular Skeleton Detected By Whole-Body Multidetector CT: Comparison With 18 f-FDG PET-CT

Yuki Nishida, M.D., Hiroki Sugihara, MD, Masayuki Yamakura, MD, Masami Takeuchi, MD, Dai Chihara, MD, Toshihiro O'uchi, MD, PhD, Kosei Matsue, MD, PhD

Blood (2013) 122 (21): 1857.

https://doi.org/10.1182/blood.V122.21.1857.1857

Published: 2013

Journal Articles

Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells

Margaret Nieborowska-Skorska, MD, PhD, Artur Slupianek, PhD, Grazyna Hoser, PhD, Elisabeth Bolton-Gillespie, PhD, Alexei Tulin, Sabine Cerny-Reiterer, D.V.M, Peter Valent, Markus Muschen, Stephen M. Sykes, PhD, Tomasz Skorski, MD, PhD

Blood (2013) 122 (21): 810.

https://doi.org/10.1182/blood.V122.21.810.810

Published: 2013

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.

Pritesh R. Patel, MB, ChB, Bulent Aydogan, PhD, Damiano Rondelli, MD

Blood (2010) 116 (21): 4526.

https://doi.org/10.1182/blood.V116.21.4526.4526

Published: 2010

Journal Articles

Contribution of PET/CT In the Design of the Involved Node Radiotherapy (INRT) Concept for Patients with Localized Hodgkin Lymphoma: Preliminary Results on 117 Patients.

Vincent Ribrag, MD, Véronique Edeline, Alijosa Celebic, Christophe Fermé, MD, Claude Ruelle, Bérénice Boulet, Théodore Girinsky, Anne Auperin

Blood (2010) 116 (21): 2817.

https://doi.org/10.1182/blood.V116.21.2817.2817

Published: 2010

Journal Articles

Expressions of G-CSF Receptor in Tumor Cells Might Stimulate the Proliferation of Malignant Cells Upon Treatment of G-CSF.

Tae Young Kim, Hee Won Moon, Bora Oh, Sang Mee Hwang, Ja-Lok Ku, Dong Soon Lee

Blood (2009) 114 (22): 1009.

https://doi.org/10.1182/blood.V114.22.1009.1009

Published: 2009

Journal Articles

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Panos Kottaridis, Janet North, Ismail Bakhsh, Edward Samuel, Stephen Mackinnon, Mark W Lowdell, PhD, FRCPath

Blood (2008) 112 (11): 2901.

https://doi.org/10.1182/blood.V112.11.2901.2901

Published: 2008

Journal Articles

Expression Level of Granulocyte-Colony Stimulating Factor Receptor and Effect of Two Forms of G-CSF to in AML1/ETO+ Acute Myelogenous Leukemia.

Heewon Moon, MD, PhD, Tae Young Kim, Hyun Chung Min, Bo Ra Oh, Sung Soo Yoon, M.D., PhD, Byoung Kook Kim, M.D., PhD, Han Ik Cho, M.D., PhD, D.S. Lee, M.D., PhD, AML/MDS Working Party

Blood (2007) 110 (11): 4298.

https://doi.org/10.1182/blood.V110.11.4298.4298

Published: 2007

Journal Articles

Differential Induction of Apoptosis in Human Leukemia Cells (ML-1, ML-2, CTV-1 and KASUMI-1) Exposed to the Proteasome Inhibitor Bortezomib and the Effect of Transforming Growth Factor-beta Signaling Pathway.

Ota Fuchs, PhD, Dana Provaznikova, MS, Gabriela Peslova, MS, Marcela Kocova, MS, Iuri Marinov, MD, Ivan Spicka, MD

Blood (2006) 108 (11): 4359.

https://doi.org/10.1182/blood.V108.11.4359.4359

Published: 2006

Journal Articles

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

Mark W. Lowdell, PhD, Ismail Bakhsh, MSc, Janet North, MSc, Chloe Marden, PhD, Elena Addison, MSc, Stephen Mackinnon, MD

Blood (2006) 108 (11): 3707.

https://doi.org/10.1182/blood.V108.11.3707.3707

Published: 2006

Journal Articles

The Residual Malignant Cells Could Be Masked by Therapeutic Use of Granulocyte-Colony Stimulating Factor in the Patients with AML1/ETO + Acute Myelogenous Leukemia.

Hee Won Moon, MD, Ho Young Kim, Young Ree Kim, MD, Han Ik Cho, MD, PhD, Sung-Soo Yoon, MD, PhD, Seonyang Park, MD, PhD, Byoung Kook Kim, MD, PhD, Honggu Chun, MD, PhD, Hee Chan Kim, MD, PhD, Dong Soon Lee, MD, PhD

Blood (2005) 106 (11): 4512.

https://doi.org/10.1182/blood.V106.11.4512.4512

Published: 2005

NARROW

Evaluating ROR1 As a Target in Childhood Leukemia

PET-CT Invisible Diffuse Large B-Cell Lymphoma Features a Silent B-Cell Receptor Signaling

Histone Deacetylation Inhibitor Sensitizes T-ALLs to Topoisomerase II Inhibitor By Attenuating G2 Cell Cycle Arrest and Blocking Nuclear Entry of Ctip during DNA Repair

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency

Prognostic Implications Of Abnormal Bone Marrow Lesions In The Appendicular Skeleton Detected By Whole-Body Multidetector CT: Comparison With 18 f-FDG PET-CT

Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.

Contribution of PET/CT In the Design of the Involved Node Radiotherapy (INRT) Concept for Patients with Localized Hodgkin Lymphoma: Preliminary Results on 117 Patients.

Expressions of G-CSF Receptor in Tumor Cells Might Stimulate the Proliferation of Malignant Cells Upon Treatment of G-CSF.

A Phase I/II Clinical Trial of Tumour-Activated Allogeneic Natural Killer Cells in AML

Expression Level of Granulocyte-Colony Stimulating Factor Receptor and Effect of Two Forms of G-CSF to in AML1/ETO+ Acute Myelogenous Leukemia.

Differential Induction of Apoptosis in Human Leukemia Cells (ML-1, ML-2, CTV-1 and KASUMI-1) Exposed to the Proteasome Inhibitor Bortezomib and the Effect of Transforming Growth Factor-beta Signaling Pathway.

Tumor-Activated Human NK Cells Specificall Ylyse Autologous and Allogeneic NK-Resistant Tumor Targets.

The Residual Malignant Cells Could Be Masked by Therapeutic Use of Granulocyte-Colony Stimulating Factor in the Patients with AML1/ETO + Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only